Published in final edited form as:

Environ Sci Technol. 2015 September 01; 49(17): 10466–10473. doi:10.1021/acs.est.5b02237.

Breastfeeding as an Exposure Pathway for Perfluorinated Alkylates

Ulla B. Mogensen[†], Philippe Grandjean^{‡,||,*}, Flemming Nielsen[‡], Pal Weihe[§], and Esben Budtz-Jørgensen[†]

[†]Department of Biostatistics, University of Copenhagen, 2200 Copenhagen, Denmark

[‡]Department of Environmental Medicine, University of Southern Denmark, 5000 Odense, Denmark

[§]Department of Occupational Medicine and Public Health, Faroese Hospital System, 100 Torshavn, Faroe Islands

^{||}Department of Environmental Health, Harvard School of Public Health, Boston, MA 02215

Abstract

Perfluorinated alkylate substances (PFASs) are widely used and have resulted in human exposures worldwide. PFASs occur in breast milk, and the duration of breastfeeding is associated with serum-PFAS concentrations in children. To determine the time-dependent impact of this exposure pathway, we examined the serum concentrations of five major PFASs in a Faroese birth cohort at birth, and at ages 11, 18, and 60 months. Information about the children's breastfeeding history was obtained from the mothers. The trajectory of serum-PFAS concentrations during months with and without breastfeeding was examined by linear mixed models that accounted for the correlations of the PFAS measurements for each child. The models were adjusted for confounders such as body size. The duration of exclusive breastfeeding was associated with increases of most PFAS concentrations by up to 30% per month, with lower increases during partial breast-feeding. In contrast to this main pattern, perfluorohexane sulfonate was not affected by breast-feeding. After cessation of breastfeeding, all serum concentrations decreased. This finding supports the evidence of breastfeeding being an important exposure pathway to some PFASs in infants.

INTRODUCTION

Perfluorinated alkylates (PFASs) are widely used to make industrial products resistant to water, oil or stains¹. PFASs can have immunotoxic effects, and a major concern is that PFAS exposure may undermine childhood immunization programs². Due to the particular vulnerability of the immune system during early development³, the sources of PFAS exposure in infants are of special interest. Concentrations of PFOS and PFOA in breast milk are generally between 20 and 100 ng/L⁴, and a daily milk intake of about 125 mL/kg body weight⁵ could easily contribute about 6 ng/kg per day or a total of 1 µg/kg for the recommended 6 months of breast-feeding⁶. These amounts may appear small, but

*Address correspondence author. pgrand@hsph.harvard.edu; phone: (617) 384-8907; fax: (617) 384-8994.

The authors declare no competing financial interests.

elimination of long-chain PFASs in humans is very slow, with half-lives in adults thought to be several years^{7–9}. PFAS concentrations in infant formulas are low^{4, 10}, and exposure via human milk could therefore lead to elevated serum concentrations in breastfed infants^{11, 12}. As a result, serum PFAS concentrations in the infant may eventually exceed those of the mother^{11, 13}.

Breastfeeding is recommended by WHO as the exclusive food source for infants during the first 6 months after birth and onwards partially with supplementary food up to age 2 years¹⁴. This recommendation focuses on the beneficial effects for both mother and child. Although WHO did not consider the possible impact of environmental chemicals present in human milk, the risks and benefits of breast-feeding has sometimes been referred to as “the weanling’s dilemma”¹⁵.

The present study examines the association between months with exclusive or partial breastfeeding and serum- PFAS concentrations in the children up to age 5.

MATERIALS AND METHODS

Human subjects.

A birth cohort of 656 children born in the Faroe Islands was formed during 1997–2000 and followed prospectively.² A serum sample and informed consent were obtained at week 32 of pregnancy. Only singleton births were included in the cohort. During a 12-month period of the follow-up period, a subgroup of mothers was invited to bring in their children for an examination and blood tests at ages 11 months and 18 months, while all children were invited for the examination at age 5 years. The prenatal exposure was assessed from the mother’s serum-PFAS concentrations at pregnancy week 32. Sufficient serum volume for chemical analysis at ages 11 or 18 months was available for 81 children and for 538 children at age 60 months.

The duration (in months) of exclusive and partial breastfeeding was obtained from the mothers, who filled in a questionnaire when the children were 5 years old. Our previous studies in this population have shown an excellent association between maternal reports on breastfeeding duration up to seven years later¹⁶. As traditional intake of pilot whale meat is a major source of PFAS exposure¹⁷, the mothers were asked whether or not the child had eaten any whale meals by age 5.

From the clinical examinations, the child’s birth weight and length as well as height and weight at subsequent follow-up were obtained to allow calculation of the ponderal index (PI; g/cm³). The ponderal index was chosen as an appropriate alternative to the body mass index to obtain a standardized measure of distribution volume during the infancy-childhood follow-up period.

Exposure assessment.

Major PFASs in serum collected at the clinical examinations were measured by online solid-phase extraction and followed by high-pressure liquid chromatography with tandem mass spectrometry^{2, 18}: perfluorohexane sulfonate (PFHxS), perfluorooctanoate (PFOA),

perfluorooctane sulfonate (PFOS), perfluorononanoate (PFNA), and perfluorodecanoate (PFDA). Quality control samples obtained from the German Quality Assurance Programme (Q-EQUAS) are included in each sample series analyzed. Within-batch imprecision (assessed by the coefficient of variation) was better than 3% and between-batch imprecision better than 5.6% for all analytes. The children's neonatal serum-PFAS concentrations was calculated based on PFAS ratios between cord and maternal pregnancy serum concentrations previously estimated for the same cohort¹⁹: 0.74 (PFHxS); 0.34 (PFOA); 0.72 (PFOS); 0.50 (PFNA); and 0.29 (PFDA).

Statistical methods.

All PFAS concentrations were log-transformed prior to the analyses to obtain normally distributed residuals of the models. The age dependence of the PFAS concentration was modeled using a piece-wise linear model:

$$Y_{i,a} = \mu_i + \alpha \text{exclusive}_{i,a} + \beta \text{mixed}_{i,a} + \gamma \text{nonmilk}_{i,a} + \epsilon_{i,a} \quad (1)$$

where $Y_{i,a}$ is the log-transformed serum concentration of child i at age a , while $\text{exclusive}_{i,a}$, $\text{mixed}_{i,a}$, and $\text{nonmilk}_{i,a}$ indicates the number of months that the child was exclusively breastfed, partially breastfed, and not breastfed at all by age a . At birth, the serum concentration is given by the intercept (μ_i) which is allowed to be specific for each child. During the period of exclusive breastfeeding, the log-transformed concentration is assumed to change by a slope of α per month. Likewise, during partial breastfeeding the slope is β , and after weaning, the slope is γ .

We first included only the three concentrations obtained at birth and at age 11 and 18 months. The model was estimated using a linear mixed model with breastfeeding variables included as covariates. Heterogeneity between children in the PFAS levels at birth was modeled by assuming that the intercept μ_i followed a normal distribution with a mean μ and a variance τ . In this way we allow for correlation between PFAS measurements from the same child. The error terms $\epsilon_{i,a}$ were assumed to follow normal distributions with mean zero and an exponential serial covariance structure ($\text{cov}(\epsilon_{i,a}, \epsilon_{i,a'}) = \sigma^2 \exp(-d_{(a,a')}/\rho)$), where $d_{a,a'}$ is the distance between age a and age a' . This addition allows serum concentrations at ages close in time to be more strongly correlated than measurements further apart.

We then extended the model to include the PFAS concentration at age 5 years and assessed the changes in serum concentrations during the period after weaning. The first model included the breastfeeding variables as described in Equation (1)

Then the analyses were repeated after adjustment for effects of sex, child size and exposure from whale meat intake at 60 months. The effect of the child's size on the serum measured concentration was modeled by including child's PI as an additional covariate so that the serum-PFAS concentration at a given age was assumed to depend on the PI at that age. We

used the PI at 12 months for correction of serum concentrations at age 11 and 18 months. Further, the concentrations at age 5 years were adjusted for whale meat intake. We also adjusted for sex and for interaction between sex and breastfeeding variables.

Serum-PFAS concentrations at birth were collected differently and may therefore have been less precise than the subsequent concentrations. In a sensitivity analyses, we therefore allowed the birth concentrations to have a larger variance than concentrations obtained later. This was done by modifying equation (1) to include a normally distributed random effect $\zeta_{i,a}$ which is non-zero only for concentrations at birth ($a=0$).

All test probabilities were two-sided, and we calculated 95% confidence intervals using robust standard errors. Although only 12 children have complete PFAS information, the mixed model analysis also includes information for in-complete cases under an assumption that data are missing at random²⁰. These statistical analyses were performed using SAS 9.4.

RESULTS

All samples contained measurable concentrations of all five PFAS compounds (Table 1). The children were breastfed exclusively for a median of 4.5 months (interquartile range, IQR: 3.5 months; 6 months), followed by partial breastfeeding with supplementary baby food for a median of 4 months (IQR: 2 months; 7 months). More than two-thirds of the children had eaten whale by age 5.

We considered the 81 children who had at least one measurement of serum-PFAS concentrations at ages 11 or 18 months. Table 1 shows the characteristics of these children. Figure 1 shows the trajectories of the five major PFAS for the 12 children with complete observations from all examinations. The child with the lowest concentrations (blue dotted line) was not breastfed at all, whereas the child with the highest PFOS concentration (black solid line) was breastfed exclusively in 6 months and was partially breastfed during the following 5 months.

Results of the linear mixed models are shown in Table 2 (left columns). In the models that include only birth, age 11 and age 18 months concentrations, a general increasing trend was found for all PFASs, with exception of PFHxS. During months with exclusive breastfeeding, significant increases in the concentrations of four PFASs occurred, ranging between 18.1% (95%CI: 12.5%, 24.1%) for PFDA to 29.2% (95%CI: 25.3%, 33.1%) for PFOS per month. For months with partial breastfeeding, the PFAS concentrations showed less apparent, though still significant increases, and only small, if any, increases were associated with the number of months without any breastfeeding. In contrast, PFHxS showed a decrease in the serum concentration during all three periods, the steepest and highly statistically significant occurring during months without breastfeeding.

To follow the longer-term development of serum-PFAS concentrations after weaning, we also included the age-5 serum concentrations (Table 2, right columns). The months with exclusive or partial breastfeeding showed similar effects on the age-60 months serum concentrations as in the models based only on the infancy data. Overall, the development of

the PFAS concentrations during months without breast feeding showed significant decreases for PFHxS, PFOA, and PFOS.

Assuming that no further exposure occurs, the slope of the (log-) curve for months without breast milk can be interpreted as a reflection of the biological half-life of the serum-PFAS concentration. We find that the child's serum concentration has decreased by half of the peak concentration at the completion of breast feeding after approximately 22 months (PFHxS), almost 50 months (PFOA), and more than 52 months (PFOS).

Predicted time-dependent serum-PFAS concentrations are shown in Figure 2 for two children who differ only in number of months with exclusive breastfeeding; one being exclusively breastfed for 4.5 months (median duration in the cohort) and one for 6 months (duration recommended by WHO¹⁴), neither of them having ever having eaten whale by age 5 years.

After adjustment for the child's PI, sex and whale intake, the changes in serum-PFAS concentrations during breast-feeding and after weaning were almost unchanged (Table 3). The PI showed a positive, though borderline significant association with the serum-PFOA concentration, while the association with the other four PFASs was negative and not statistically significant. The children who consumed at least one whale meal before age 5 had up to 31.9% (95%CI: -6.9%, 86.6%) higher serum-PFAS concentrations compared to the children who had not eaten whale, but there was no statistically significant difference in the PI between children who had eaten whale and those who had not. Also we found no statistically significant differences between boys and girls in PFAS concentrations levels (Table 3) and interaction terms with breast feeding variables were also not significant. Finally, the sensitivity analysis allowing for additional variation in concentrations at birth did not lead to important changes in the estimated effects of breastfeeding variables.

Neither were there any statistically significant difference in PFAS concentrations between boys and girls.

DISCUSSION

The present study aimed at examining the profile of serum-PFAS concentrations during the first 5 years after birth. Because of the substantial number of children examined in a prospective design, the results add considerable information to current insight into PFAS exposures and kinetics. As PFAS may occur in elevated concentrations in human milk^{11, 12}, as compared to infant formulas^{4, 10} neonatal exposures were assumed to depend on the duration of breast-feeding²¹. As we used log scale transformations of PFAS concentrations, the higher milk concentrations from mothers with elevated serum concentrations^{12, 13} were included in the model by default. However, neither the newborn baby's PFAS concentrations and the concentrations in milk were measured in this study, which instead relied on the maternal serum concentrations measured at a specified point during pregnancy. Although the reliance on maternal serum may be a limitation of this study, it avoids variability in cord serum associated with gestational age and in milk levels associated with the time of sampling. Our results show that four of the major PFASs tended to increase substantially

during the breast-feeding period, thereby suggesting that human milk is a main source of exposure during infancy. The peak serum concentration was reached at the completion of breast-feeding and was relatively greater for PFOA than for PFNA that was greater than for PFDA, thus suggesting a possible dependence on chain length.

However, the steep *decrease* in the children's serum-PFHxS concentrations during the nursing period – in contrast to the steep *increases* for the other PFASs measured – suggest that early postnatal PFHxS exposure in the Faroes mainly originates from sources other than human milk. Although the calculated neonatal serum concentration may have been slightly inaccurate, the results based on all 81 children, whether breastfed or formula-fed, support the trend of decreasing serum concentrations of this PFAS during early childhood in this community. Our study did not attempt to characterize other exposure sources, apart from whale meat intake. Due to the wide variety of PFAS uses,¹ multiple indoor sources²² and food items²³ can potentially contribute to human exposures, also during childhood. We note that PFHxS has been used to stain-proof upholstery and carpets and therefore also occurs in house dust,^{24, 25} which may constitute an important exposure source in later childhood and onwards. Such sources may explain the increases in serum-PFHxS concentrations shown in Figure 1. Although this figure is based on only twelve subjects with complete data, the general pattern is similar to those seen in Figure 2 based on the complete study group, where missing data were modeled.

While human milk is unlikely to be the sole source of exposure, a PFAS transfer of 1 µg/kg during 6 months of exclusive breast-feeding⁶ would support the notion that human milk could be the dominant exposure source for infants. Because the cohort children were breast-fed for different durations, exclusively and partially, we were able to calculate the associations between serum concentrations and lactational exposure. Our results are also in agreement with previous reports that exposures from baby food were negligible.^{4, 10}

The calculated elimination half-lives are in reasonable accordance with previous reports based on serum-PFAS concentration profiles in adults. More specifically, a half-life of 5.4 years for PFOS in retired workers is quite similar to our calculation of 53 months (4.4 years) for children. Likewise, our finding of 50 months (4.2 years) for PFOA in children is reasonably similar, though somewhat higher than estimates for adults of 3.8 years⁷ and 2.3 years⁹. However, our finding of 22 months for PFHxS months is much lower than the estimated half-life of 8.6 years in adults⁷. All of these studies relied on serial serum measurements following a peak exposure, while assuming that subsequent exposures were negligible. As this assumption is likely to be wrong, the half-lives are most probably exaggerated. Also, it should be noted that the present study relied on blood samples obtained from infants and children after parental consent, and that substantial attrition may mean the study population differs in some respects from the background population. Thus, no definite conclusion can be drawn at this point whether elimination kinetics in children differs from adults. Nonetheless, the results support the notion that the PFASs accumulate in the human body, and these data may be useful to extend modeling studies that calculate the long-term build-up of PFASs in the body starting at early development.²⁶

Adverse effects of PFASs reported in children with similar serum-PFAS concentrations include immunotoxicity, as revealed by decreased antibody concentrations toward childhood vaccines² and increased frequency of common infections²⁷. Given the importance of postnatal development of acquired immune function, the shape of the serum concentration profile may be important for PFAS-associated immune deficits. Our recent study² focused on serum concentrations measured only prenatally and at age 5 and may therefore have underestimated the impact of the changes in serum-PFAS concentrations during infancy. The results of the present study suggest that future research should more closely monitor early postnatal PFAS exposures, especially during the breast-feeding period.

One final issue is worth consideration. Breast-feeding represents an excretion pathway for the mother, although apparently not for PFHxS. Serial analyses of human milk have shown that concentrations of PFOA and PFOS may decrease by an average of 46% and 18% during 6 months of breast-feeding¹¹. Calculations based on cross-sectional data also support the conclusion that breast-feeding leads to higher serum concentrations in the child and lower in the mother²¹. These findings suggest that several months of breast-feeding may substantially lower the mother's own body burden, thereby possibly representing a maternal advantage.

ACKNOWLEDGMENTS

This study was supported by the National Institute of Environmental Health Sciences, NIH (ES012199); the U.S. Environmental Protection Agency (R830758); the Danish Council for Strategic Research (09-063094); and the Danish Environmental Protection Agency as part of the environmental support program DANCEA (Danish Cooperation for Environment in the Arctic).

References

1. Lindstrom AB; Strynar MJ; Libelo EL, Polyfluorinated compounds: past, present, and future. *Environ Sci Technol* 2011, 45, (19), 7954–61. [PubMed: 21866930]
2. Grandjean P; Andersen E; Budtz-Jørgensen E; Nielsen F; Mølbak K; Weihe P; Heilmann C, Serum Vaccine Antibody Concentrations in Children Exposed to Perfluorinated Compounds. *JAMA* 2012, 307, (4), 391–7. [PubMed: 22274686]
3. Barouki R; Gluckman PD; Grandjean P; Hanson M; Heindel JJ, Developmental origins of non-communicable disease: implications for research and public health. *Environmental health : a global access science source* 2012, 11, (1), 42. [PubMed: 22715989]
4. Lankova D; Lacina O; Pulkrabova J; Hajslova J, The determination of perfluoroalkyl substances, brominated flame retardants and their metabolites in human breast milk and infant formula. *Talanta* 2013, 117, 318–25. [PubMed: 24209347]
5. U.S. EPA., Exposure Factors Handbook 2011 Edition (Final) In U.S. Environmental Protection Agency, Washington, DC, : 2011.
6. Raab U; Albrecht M; Preiss U; Volkel W; Schwegler U; Fromme H, Organochlorine compounds, nitro musks and perfluorinated substances in breast milk - results from Bavarian Monitoring of Breast Milk 2007/8. *Chemosphere* 2013, 93, (3), 461–7. [PubMed: 23856469]
7. Olsen GW; Burris JM; Ehresman DJ; Froehlich JW; Seacat AM; Butenhoff JL; Zobel LR, Half-life of serum elimination of perfluorooctanesulfonate, perfluorohexanesulfonate, and perfluorooctanoate in retired fluorochemical production workers. *Environ Health Perspect* 2007, 115, (9), 1298–305. [PubMed: 17805419]
8. Egeghy PP; Lorber M, An assessment of the exposure of Americans to perfluorooctane sulfonate: a comparison of estimated intake with values inferred from NHANES data. *Journal of exposure science & environmental epidemiology* 2011, 21, (2), 150–68. [PubMed: 20145679]

9. Bartell SM; Calafat AM; Lyu C; Kato K; Ryan PB; Steenland K, Rate of decline in serum PFOA concentrations after granular activated carbon filtration at two public water systems in Ohio and West Virginia. *Environ Health Perspect* 2010, 118, (2), 222–8. [PubMed: 20123620]
10. Llorca M; Farre M; Pico Y; Teijon ML; Alvarez JG; Barcelo D, Infant exposure of perfluorinated compounds: levels in breast milk and commercial baby food. *Environ Int* 2010, 36, (6), 584–92. [PubMed: 20494442]
11. Thomsen C; Haug LS; Stigum H; Froshaug M; Broadwell SL; Becher G, Changes in concentrations of perfluorinated compounds, polybrominated diphenyl ethers, and polychlorinated biphenyls in Norwegian breast-milk during twelve months of lactation. *Environ Sci Technol* 2010, 44, (24), 9550–6. [PubMed: 21090747]
12. Karrman A; Ericson I; van Bavel B; Darnerud PO; Aune M; Glynn A; Lignell S; Lindstrom G, Exposure of perfluorinated chemicals through lactation: levels of matched human milk and serum and a temporal trend, 1996–2004, in Sweden. *Environ Health Perspect* 2007, 115, (2), 226–30. [PubMed: 17384769]
13. Mondal D; Lopez-Espinosa MJ; Armstrong B; Stein CR; Fletcher T, Relationships of perfluorooctanoate and perfluorooctane sulfonate serum concentrations between mother-child pairs in a population with perfluorooctanoate exposure from drinking water. *Environ Health Perspect* 2012, 120, (5), 752–7. [PubMed: 22271837]
14. Section on B, Breastfeeding and the use of human milk. *Pediatrics* 2012, 129, (3), e827–41. [PubMed: 22371471]
15. Grandjean P; Jensen AA, Breastfeeding and the weanling's dilemma. *Am J Public Health* 2004, 94, (7), 1075; author reply 1075–6. [PubMed: 15226118]
16. Jensen TK; Grandjean P; Jorgensen EB; White RF; Debes F; Weihe P, Effects of breast feeding on neuropsychological development in a community with methylmercury exposure from seafood. *Journal of exposure analysis and environmental epidemiology* 2005, 15, (5), 423–30. [PubMed: 15674318]
17. Weihe P; Kato K; Calafat AM; Nielsen F; Wanigatunga AA; Needham LL; Grandjean P, Serum concentrations of polyfluoroalkyl compounds in Faroese whale meat consumers. *Environ Sci Technol* 2008, 42, (16), 6291–5. [PubMed: 18767701]
18. Jensen TK; Andersen LB; Kyhl HB; Nielsen F; Christesen HT; Grandjean P, Association between perfluorinated compound exposure and miscarriage in Danish pregnant women. *PLoS One* 2015, 10, (4), e0123496. [PubMed: 25848775]
19. Needham LL; Grandjean P; Heinzow B; Jorgensen PJ; Nielsen F; Patterson DG, Jr.; Sjodin A; Turner WE; Weihe P, Partition of environmental chemicals between maternal and fetal blood and tissues. *Environ Sci Technol* 2011, 45, (3), 1121–6. [PubMed: 21166449]
20. Little RJ; Rubin DB, *Statistical analysis with missing data*. John Wiley & Sons: 2014.
21. Mondal D; Weldon RH; Armstrong BG; Gibson LJ; Lopez-Espinosa MJ; Shin HM; Fletcher T, Breastfeeding: a potential excretion route for mothers and implications for infant exposure to perfluoroalkyl acids. *Environ Health Perspect* 2014, 122, (2), 187–92. [PubMed: 24280536]
22. Shoeib M; Harner T; G MW; Lee SC, Indoor sources of poly- and perfluorinated compounds (PFCS) in Vancouver, Canada: implications for human exposure. *Environ Sci Technol* 2011, 45, (19), 7999–8005. [PubMed: 21332198]
23. Domingo JL, Health risks of dietary exposure to perfluorinated compounds. *Environ Int* 2012, 40, 187–95. [PubMed: 21864910]
24. Kato K; Calafat AM; Needham LL, Polyfluoroalkyl chemicals in house dust. *Environ Res* 2009, 109, (5), 518–23. [PubMed: 19261270]
25. D'Hollander W; Roosens L; Covaci A; Cornelis C; Reynders H; Campenhout KV; Voogt P; Bervoets L, Brominated flame retardants and perfluorinated compounds in indoor dust from homes and offices in Flanders, Belgium. *Chemosphere* 2010, 81, (4), 478–87. [PubMed: 20709355]
26. Loccisano AE; Longnecker MP; Campbell JL, Jr.; Andersen ME; Clewell HJ, 3rd, Development of PBPK models for PFOA and PFOS for human pregnancy and lactation life stages. *Journal of toxicology and environmental health. Part A* 2013, 76, (1), 25–57. [PubMed: 23151209]

27. Granum B; Haug LS; Namork E; Stolevik SB; Thomsen C; Aaberge IS; van Loveren H; Lovik M; Nygaard UC, Pre-natal exposure to perfluoroalkyl substances may be associated with altered vaccine antibody levels and immune-related health outcomes in early childhood. *J Immunotoxicol* 2013, 10, (4), 373–9. [PubMed: 23350954]

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript

Figure 1: PFAS trajectories for 12 children with complete data on serum-PFAS concentrations at ages 0, 11, 18, and 60 months. Note the different exposure scales.

Figure 2: Predicted PFAS trajectories for two children breastfed exclusively for 4.5 months (average for the cohort) and 6 months (WHO recommendation), both being partially breastfed during the subsequent 4 months.

Table 1.

Characteristics of 81 members of the Faroese birth cohort with serum-PFAS concentrations at birth and at ages 11, 18, and 60 months.

Variable	Birth			Age 11 months			Age 18 months			Age 60 months		
	N (%)	Median (IQR)	N (%)	Median (IQR)	N (%)	Median (IQR)	N (%)	Median (IQR)	N (%)	Median (IQR)	N (%)	Median (IQR)
Sex (Number, girls (%))	81 (100%)	32 (39.5%)	--	--	--	--	--	--	--	--	--	--
Age (months)	81 (100%)	0 (0.0)	68 (83.95%)	10.8 (10.8,10.8)	70 (86.42%)	17.3 (16.7,18.4)	76 (93.83%)	59.4 (59.1,59.8)	76 (93.83%)	59.4 (59.1,59.8)	76 (93.83%)	59.4 (59.1,59.8)
PI (kg/m ³)	81 (100%)	22.5 (21.23,9)	69 (85.19%)	21.7 (20.6,23.0)	69 (85.19%)	21.7 (20.6,23.0)	76 (93.83%)	14.7 (13.9,15.5)	76 (93.83%)	14.7 (13.9,15.5)	76 (93.83%)	14.7 (13.9,15.5)
Whale intake (Number, yes (%))	--	--	--	--	--	--	--	--	74 (91.36%)	53 (70.7%)	74 (91.36%)	53 (70.7%)
Breast-feeding (months)												
Exclusively	81 (100%)	0	73 (90.12%)	4.5 (3.5,6.0)	73 (90.12%)	4.5 (3.5,6.0)	73 (90.12%)	4.5 (3.5,6.0)	73 (90.12%)	4.5 (3.5,6.0)	73 (90.12%)	4.5 (3.5,6.0)
Partial	81 (100%)	0	73 (90.12%)	4.0 (2.0,5.0)	73 (90.12%)	4.0 (2.0,7.0)	73 (90.12%)	4.0 (2.0,7.0)	73 (90.12%)	4.0 (2.0,7.0)	73 (90.12%)	4.0 (2.0,7.0)
None	81 (100%)	0	75 (92.59%)	1.8 (0.5,3.0)	75 (92.59%)	8.7 (5.2,11.5)	75 (92.59%)	50.3 (47.6,54.4)	75 (92.59%)	50.3 (47.6,54.4)	75 (92.59%)	50.3 (47.6,54.4)
Serum concentration (ng/mL)												
PFOS	80 (98.77%)	6.0 (5.2,7.2)	68 (83.95%)	23.2 (14.9,34.7)	33 (40.74%)	24 (20.2,29.1)	71 (87.65%)	13.3 (10.6,16.6)	71 (87.65%)	13.3 (10.6,16.6)	71 (87.65%)	13.3 (10.6,16.6)
PFOA	80 (98.77%)	2.0 (1.7,2.7)	68 (83.95%)	8.2 (6.1,10.9)	33 (40.74%)	6.1 (5.1,10)	71 (87.65%)	3.8 (3.1,4.9)	71 (87.65%)	3.8 (3.1,4.9)	71 (87.65%)	3.8 (3.1,4.9)
PFHxS	80 (98.77%)	1.9 (1.3,2.8)	68 (83.95%)	0.8 (0.5,1.1)	33 (40.74%)	0.8 (0.6,1.0)	71 (87.65%)	0.5 (0.3,0.7)	71 (87.65%)	0.5 (0.3,0.7)	71 (87.65%)	0.5 (0.3,0.7)
PFNA	80 (98.77%)	0.3 (0.2,0.4)	68 (83.95%)	0.8 (0.4,1.1)	33 (40.74%)	0.8 (0.5,1.0)	71 (87.65%)	0.9 (0.8,1.2)	71 (87.65%)	0.9 (0.8,1.2)	71 (87.65%)	0.9 (0.8,1.2)
PFDA	80 (98.77%)	0.1 (0.1,0.1)	68 (83.95%)	0.2 (0.1,0.3)	33 (40.74%)	0.2 (0.1,0.2)	71 (87.65%)	0.3 (0.2,0.4)	71 (87.65%)	0.3 (0.2,0.4)	71 (87.65%)	0.3 (0.2,0.4)

^aCount and percentage.

Abbreviations: Median, geometric mean. IQR, interquartile range. PI, ponderal index

EBJ jeg har indsat to gange “0” – jeg håber at det er rigtigt – undgå dette format en anden gang.

Table 2:

Percentage change in serum-PFAS concentrations per month during exclusive breast-feeding, partial, and none.

PFAS (ng/mL)	Variable	Mixed model up to 18 months			Mixed model up to 60 months		
		Change	95%CI	p-value	Change	95%CI	p-value
PFOS	Exclusive	29.2	(25.3, 33.1)	<.0001	30.2	(26.2, 34.3)	<.0001
	Partial	4.4	(1.0, 7.8)	0.0108	1.0	(-1.2, 3.2)	0.3762
	None	0.7	(-0.5, 1.9)	0.2693	-0.9	(-1.2, -0.6)	<.0001
PFOA	Exclusive	27.8	(23.6, 32.1)	<.0001	31.2	(28.0, 34.5)	<.0001
	Partial	3.9	(0.5, 7.3)	0.0252	0.1	(-1.6, 1.9)	0.8951
	None	0.7	(-1.1, 2.5)	0.4528	-1.3	(-1.5, -1.0)	<.0001
PFHXS	Exclusive	-1.0	(-7.9, 6.3)	0.7723	-7.5	(-12.1, -2.7)	0.0032
	Partial	-4.2	(-8.9, 0.7)	0.0874	1.3	(-1.4, 4.0)	0.3518
	None	-9.3	(-10.9, -7.6)	<.0001	-1.2	(-1.5, -1.0)	<.0001
PFNA	Exclusive	20.8	(15.7, 26.1)	<.0001	19.6	(15.9, 23.3)	<.0001
	Partial	5.2	(1.0, 9.6)	0.0172	2.9	(0.7, 5.3)	0.0108
	None	-1.5	(-2.8, -0.2)	0.0303	0.7	(0.5, 1.0)	<.0001
PFDA	Exclusive	18.1	(12.5, 24.1)	<.0001	16.1	(12.2, 20.1)	<.0001
	Partial	4.8	(0.2, 9.7)	0.0412	3.3	(0.8, 5.8)	0.0099
	None	-0.2	(-2.7, 2.4)	0.8924	1.3	(0.9, 1.6)	<.0001

Table 3:

Percentage change in serum-PFAS concentrations per month during exclusive breast-feeding, partial, and none, as compared to the effect of a 10% increase in ponderal index (PI) and whale intake. All results are adjusted for changes in PI and whale intake.

PFAS (ng/mL)	Variable	Mixed model up to 18 months			Mixed model up to 60 months		
		Change	95%CI	p-value	Change	95%CI	p-value
PFOS	Exclusive	30.0	(26.0, 34.0)	<.0001	30.5	(26.4, 34.8)	<.0001
	Partial	3.2	(0.0, 6.5)	0.0481	0.6	(-1.5, 2.7)	0.6021
	None	1.0	(-0.1, 2.2)	0.0738	-0.9	(-1.4, -0.3)	0.0012
	PI	-3.5	(-7.7, 0.9)	0.1137	-0.2	(-4.8, 4.6)	0.9251
	Whale	--	--	--	0.2	(-17.3, 21.4)	0.9834
	Sex (boy vs girl)	-4.9	(-16.0, 7.7)	0.4248	-4.3	(-16.8, 10.0)	0.5349
PFOA	Exclusive	29.0	(24.8, 33.4)	<.0001	29.7	(25.6, 34.0)	<.0001
	Partial	2.6	(-0.4, 5.7)	0.0893	0.1	(-2.1, 2.5)	0.9059
	None	0.8	(-1.0, 2.7)	0.3909	-0.6	(-1.1, 0.0)	0.0567
	PI	0.5	(-4.8, 6.1)	0.8555	5.3	(0.0, 10.8)	0.0479
	Whale	--	--	--	-2.8	(-20.6, 19.1)	0.7851
	Sex (boy vs girl)	-6.0	(-20.8, 11.6)	0.4762	-2.0	(-17.6, 16.6)	0.8206
PFHXS	Exclusive	-3.6	(-10.2, 3.4)	0.2990	-7.5	(-12.5, -2.2)	0.0060
	Partial	-2.0	(-6.5, 2.7)	0.3972	0.9	(-2.1, 4.0)	0.5539
	None	-9.1	(-10.8, -7.3)	<.0001	-2.4	(-3.4, -1.4)	<.0001
	PI	2.7	(-5.2, 11.2)	0.5081	-3.6	(-11.0, 4.4)	0.3688
	Whale	--	--	--	31.9	(-6.9, 86.8)	0.1189
	Sex (boy vs girl)	-0.3	(-17.8, 21.0)	0.9794	10.0	(-12.3, 38.1)	0.4071
PFNA	Exclusive	21.1	(15.5, 26.9)	<.0001	20.5	(16.5, 24.6)	<.0001
	Partial	4.3	(-0.1, 8.9)	0.0530	2.5	(-0.1, 5.1)	0.0606
	None	-1.0	(-2.0, 0.1)	0.0838	0.3	(-0.1, 0.8)	0.1581
	PI	-4.9	(-9.6, 0.2)	0.0579	-2.1	(-6.3, 2.3)	0.3393
	Whale	--	--	--	15.3	(-10.2, 48.2)	0.2622
	Sex (boy vs girl)	7.3	(-11.0, 9.2)	0.4380	8.6	(-7.7, 27.8)	0.3160
PFDA	Exclusive	17.3	(11.1, 23.8)	<.0001	16.3	(12.1, 20.7)	<.0001
	Partial	4.7	(-0.5, 10.1)	0.0732	2.9	(0.1, 5.9)	0.0452
	None	0.6	(-1.5, 2.8)	0.5608	1.0	(0.5, 1.5)	0.0002
	PI	-4.3	(-9.8, 1.6)	0.1374	-1.2	(-5.7, 3.5)	0.6022
	Whale	--	--	--	11.2	(-11.4, 39.7)	0.3564
	Sex (boy vs girl)	0.2	(-17.5, 21.6)	0.9869	0.1	(-14.1, 16.7)	0.9875